-
Company Profile
Societe Generale SA – Company Profile
Societe Generale SA (SG) is a provider of banking and financial services. Its product offering comprises insurance, accounts, cards, deposits, financing, equities, fixed income and currencies, and alternative investments. SG’s service portfolio consists of fleet management, leasing, advisory, financing, investment and risk management, asset solutions, private banking services, wealth planning, investment management, securities services, and consulting. SG operates through a network of branch and representative offices, ATMs, and online portals and caters to individual, commercial, SME, high net worth individual,...
Add to Basket -
Sector Analysis
China Contract Manufacturing Market Outlook – Trends, Ambitions, Key Players, Investment and Value Chain
There is an increasing reliance on contract manufacturing and development services due to the growing regulatory complexity surrounding drug production and development. China has been focusing on establishing volume and enhancing capabilities for innovative high-value drug production. This will enable the Chinese pharma manufacturers to compete with US and European equivalents in terms of obtaining contracts for lucrative treatments such as gene and cell therapies. China is also upgrading its manufacturing capabilities, boosting innovation, and strengthening its position in a...
-
Product Insights
Ornithine-Transcarbamylase Deficiency Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ornithine transcarbamylase (OTC Deficiency) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC Deficiency). OTC Deficiency plays an important role in the break down and removal of nitrogen in the body (urea cycle). The lack of the OTC Deficiency enzyme results in excessive accumulation of nitrogen, in the form of ammonia (hyperammonemia), in the blood. Symptoms include vomiting, refusal to eat, progressive lethargy, and coma. The Ornithine-Transcarbamylase (OTC Deficiency) Deficiency...
-
Sector Analysis
COVID-19: Contract Pharmaceutical Development and Manufacturing Relationships
This report examines contract manufacturing agreements for vaccines and therapies targeting COVID-19. It reports that there are more than 1,000 vaccines and therapies in development for COVID-19, and 36 vaccines and therapies approved (or granted emergency use authorization) for COVID-19 (as of report publication). At the beginning of the pandemic, slightly more than half of these agreements were for vaccines; this proportion has risen and continues to rise, as several vaccines have proven their safety and efficacy, received approval, and...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Vaccines – Contract Development and Manufacturing Landscape
This expert trend report is a comprehensive look at the contract manufacturing landscape surrounding COVID-19 Vaccine in 2020, including analysis of pipeline drugs, clinical trials, CMO activity, Contract Manufacturing Service Agreements, and funding for manufacturing of COVID-19 Vaccines. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...
-
Product Insights
African Trypanosomiasis Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “African Trypanosomiasis Global Clinical Trials Review, H2, 2018" provides an overview of African Trypanosomiasis clinical trials scenario. This report provides top line data relating to the clinical trials on African Trypanosomiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
African Trypanosomiasis Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “African Trypanosomiasis Global Clinical Trials Review, H1, 2017" provides an overview of African Trypanosomiasis clinical trials scenario. This report provides top line data relating to the clinical trials on African Trypanosomiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Steam Generators For Nuclear Power, Update 2016 – Global Market Size, Competitive Landscape and Key Country Analysis to 2025
GlobalData’s latest report “Steam Generators For Nuclear Power, Update 2016 - Global Market Size, Competitive Landscape and Key Country Analysis to 2025” provides comprehensive information and understanding of the steam generators (SGs) market for nuclear power. The report offers in-depth analysis of SGs market at global, regional (North America, Europe and Asia-Pacific) and key countries (the US, Canada, France, Russia, Ukrain, the UK, China, India, Japan, Republic of Korea, UAE, Turkey and Vietnam) level. The report includes the global, regional...